Karah Herdman Parschauer - Mar 1, 2022 Form 4 Insider Report for Ultragenyx Pharmaceutical Inc. (RARE)

Role: EVP and Chief Legal Officer
Signature: /s/ Karah Parschauer
Stock symbol: RARE
Transactions as of: Mar 1, 2022
Transactions value $: -$192,265
Form type: 4
Date filed: 3/3/2022, 05:08 PM
Previous filing: Jan 26, 2022
Next filing: Mar 8, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RARE	Common Stock	Sale	-$192K	-2.89K	-10.18%	$66.62	25.5K	Mar 1, 2022	Direct	F1, F2
transaction	RARE	Common Stock	Award	$0	+14K	+54.73%	$0.00	39.6K	Mar 1, 2022	Direct	F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RARE	Stock Option (Right to Buy)	Award	$0	+24.9K		$0.00	24.9K	Mar 1, 2022	Common Stock	24.9K	$67.37	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs").
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.62 to $66.63 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3	Includes 106 shares acquired under the Company's 2014 Employee Stock Purchase Plan on October 29, 2021.
F4	Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
F5	On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date.